Radioligand Therapy Explained: Why Scientific Informatics Matters

An accessible industry overview of the science, clinical workflow, commercialization challenges, and data foundation behind targeted radiopharmaceuticals

By

Charlie Fetsko, 20/15 Visioneer Intern

Overview

Radioligand therapy (RLT) is a rapidly advancing form of precision cancer treatment that uses a tumor-seeking molecule to carry radiation directly to cancer cells. Unlike external-beam radiation therapy, which directs radiation into the body from an external source, RLT travels through the bloodstream and seeks cells that express a specific biological marker. This approach can deliver radiation to tumors throughout the body, including metastatic disease, while limiting, but not eliminating, exposure to healthy tissue.

A radioligand has two principal components: a targeting molecule, known as the ligand, and a radioactive isotope, or radionuclide. The ligand acts like a biological address label, recognizing and binding to a specific receptor or protein on the tumor. The radionuclide provides either an imaging signal or therapeutic radiation capable of damaging the cancer cell.

RLT is often part of a broader strategy known as theranostics, which connects diagnosis and therapy through the same biological target. A diagnostic radiopharmaceutical and imaging scan, typically PET or SPECT, are first used to determine whether the target is present and where the disease is located. If the tumor demonstrates sufficient uptake, a corresponding therapeutic radiopharmaceutical can be administered to deliver radiation to those target-positive sites. Imaging, dosimetry, and clinical monitoring may then be used to evaluate radiation exposure, treatment response, and potential toxicity.

Although the concept can be explained simply, developing and delivering RLT is extraordinarily complex. Success depends on a tightly coordinated chain that includes isotope production, radiochemistry, ligand development, sterile manufacturing, rapid quality control, time-sensitive transportation, diagnostic imaging, patient selection, dosimetry, treatment administration, and follow-up care. Because radioactive materials decay continuously, delays or failures anywhere in this chain can affect product quality, patient scheduling, clinical outcomes, and commercial viability.

This complexity produces an equally demanding data environment. Discovery results, chemical structures, isotope characteristics, manufacturing records, quality data, imaging, dosimetry, clinical observations, and supply-chain information must remain connected, contextualized, and traceable. Scientific informatics therefore becomes more than laboratory support, it provides the foundation needed to coordinate the RLT lifecycle, maintain data integrity, improve decision-making, and prepare model-quality data for advanced analytics and artificial intelligence. 

This paper introduces the science behind RLT, explains its diagnostic and therapeutic workflows, examines the development and commercialization challenges facing the industry, and explores how scientific informatics and AI can help the field scale safely, efficiently, and reproducibly.

Figure 1. Schematic of radioligand therapy components and functions. Sourced from Radioligand Therapy in Cancer Management: A Global Perspective. 

Depending on the isotope and the intended usage, the radioisotope could emit alpha, beta, or gamma radiation. Alpha particles (comprised of 2 protons and 2 neutrons) have a high linear energy transfer, allowing them to deposit large amounts of energy over a short distance and produce complex double-strand DNA breaks that cancer cells struggle to repair. Alpha particles have a more localized effect due to their shorter tissue penetration. Many alpha emitting RLT, such as Actinium-225 PSMA, are still in clinical trial or early clinical use stages. Beta particles (an electron or positron) have a lower linear energy transfer, but can penetrate further into the tissue, allowing them to deliver radiation to neighboring tumor cells that have not taken up the radioligand. Beta emitting RLT is more well established clinically and typically less toxic than alpha RLT. Lutetium-177, used for both prostate cancer and neuroendocrine tumors, emits both beta particles and gamma photons. Gamma rays, which are high energy photons rather than particles, can travel much farther through the tissue. Gamma radiation is employed more often in the imaging and monitoring stages than for therapeutic usage.

Diagnostics

Radioligands are first employed in diagnostic imaging to confirm that the tumor expresses the target in sufficient quantity for RLT to be suitable. Positron emission tomography (PET) and single photon emission computed tomography (SPECT) utilize radionuclides to evaluate the target expression and map the extent of the disease. An individualized eligibility assessment must be performed to ensure adequate tumor uptake and acceptable kidney and bone marrow function. Treatment planning and monitoring are required to evaluate medication dosage and responsiveness to the treatment.

Currently, there are two main diagnostic imaging approaches: PSMA PET for prostate cancer and somatostatin receptor PET for neuroendocrine tumors. For metastatic castration-resistant prostate cancer, the most common diagnostic study is Gallium-68 PSMA PET/CT or Fluorine-18 PSMA PET/CT. These scans identify tumors expressing prostate-specific membrane antigen (PSMA). If sufficient PSMA uptake is present, lutetium-177 PSMA therapy may be employed. Patients with well-differentiated neuroendocrine tumors are commonly evaluated using Gallium-68 DOTATATE PET/CT, Gallium-68 DOTATOC PET/CT, or Copper-64 DOTATATE PET/CT. These tracers bind somatostatin receptor subtype 2 (SSTR2). High uptake predicts suitability for peptide receptor radionuclide therapy (PRRT) using lutetium-177 DOTATATE. Research is expanding theranostics to additional molecular targets, including fibroblast activation protein (FAP), gastrin-releasing peptide receptor (GRPR), and others, though many remain in clinical trials or early clinical adoption.

Treatment

The treatment stage of RLT involves administering the therapeutic radiopharmaceuticals that selectively bind to tumor cells and deliver cytotoxic radiation. Unlike conventional external beam radiation therapy, which irradiates tissues from outside the body, RLT delivers radiation internally by targeting specific molecular markers expressed on cancer cells. This targeted approach aims to maximize tumor irradiation while minimizing exposure to surrounding healthy tissues.

After a pre-treatment assessment, the therapeutic agent, such as lutetium-177 PSMA or lutetium-177 DOTATATE, is prepared and administered by intravenous infusion. After entering the bloodstream, the ligand binds to its target receptor or antigen on tumor cells and the complex is internalized by the cell. The radionuclide emits ionizing radiation that damages cellular DNA, leading to cell death or loss of reproductive capacity. Because radiation travels only a limited distance, most of the dose is concentrated within the tumor and nearby tumor cells.

Developments

Most approved RLTs currently use beta-emitting radionuclides, such as lutetium-177. An important area of research is the use of alpha-emitting radionuclides.  Alpha particles have much higher linear energy transfer, greater biological effectiveness, and very short tissue penetration. These properties enable highly localized tumor cell killing while potentially reducing radiation exposure to surrounding healthy tissue. 

Traditionally, many patients receive fixed administered activities. Increasingly, researchers are developing patient-specific dosimetry, which estimates radiation absorbed by tumors and select organs. Using serial imaging and computational modeling, clinicians can individualize treatment to maximize tumor dose while limiting toxicity. Advances in ligand engineering are producing radiopharmaceuticals with higher receptor affinity, improved tumor retention, faster clearance from non-target tissues, reduced kidney and salivary gland uptake, and greater in vivo stability. New linker molecules, chelators, and targeting peptides are also being developed to optimize pharmacokinetics and therapeutic performance. 

Constraints

Radioisotope supply constraints are one of the largest commercialization bottlenecks. Many therapeutic isotopes like Lutetium-177, Actinium-225, and Copper-67, have limited global production. Limited worldwide production sites, aging nuclear reactors, competition from research and diagnostics use, and geopolitical dependence on select suppliers are all barriers to maintaining dependable radioisotope supplies. These factors cause revenue to be capped by isotope availability rather than patient demand and may cause companies to delay launches or limit geographic expansion. 

Unlike many conventional biologics, the manufacturing complexity of radioligands involves synthesis of the targeting ligand, radiolabeling, sterile manufacturing, radiation safety, rapid quality control, and shipment before radioactive decay significantly reduces activity. Since every production batch is time-sensitive, operations are more akin to just-in-time manufacturing than traditional pharmaceutical production. This generates challenges like low manufacturing yields, a need for specialized facilities, radiation-shielded equipment, regulatory oversight, and high capital expenditure. Distribution and logistics become complicated by the nature of radioligands, as radioactive decay creates a "use it or lose it" problem. Many PET isotopes have very short half-lives of minutes to hours. Commercial implications include limited shipping radius, cold-chain and radiation-compliant transport, customs delays for international shipments, and scheduling failures if patients cancel. 

Most RLTs rely on imaging to identify eligible patients, such as PET scans targeting the same molecular marker as the therapy. This dual nature of nuclear theranostics adds another layer of complexity in selecting and manufacturing suitable radioisotopes. Finding a validated companion diagnostic with similar chemical properties and half-life poses a distinct challenge. Separate manufacturing and reimbursement pathways may be required for the theranostic pair. Additional regulatory submissions may be required, and the coordination between imaging and treatment services becomes more complex. This increases development costs and can complicate market access. 

Because RLT products are regulated as both pharmaceuticals and radioactive materials, the regulatory complexity adds another challenge. Sponsors may need to satisfy drug quality requirements, radiation safety standards, transport regulations, nuclear licensing requirements, and environmental disposal rules. Additionally, requirements can vary substantially across countries, making global launches more complex.

Reimbursement uncertainty may deter investment in RLT development. As outlined above, RLTs are often expensive because they incorporate specialized manufacturing, isotope production, advanced imaging techniques, hospital administration, and multidisciplinary care. Without robust evidence to display the economic benefits and effectiveness of the therapy, payers may question the practicality of investing in this treatment. Since many radioisotopes themselves cannot be patented, intellectual property limitations may discourage companies from investing in RLT development. Competitive advantages can be built around the targeting ligands, the chelation chemistry, manufacturing methods, isotope production technologies, companion diagnostics, or dosing regimens. This can make long-term market exclusivity more challenging than for some small-molecule drugs.

As you might imagine at this point, RLT clinical trials are more complex than many conventional oncology studies. They require specialized imaging for enrollment followed by dosimetry assessments at experienced treatment centers. A constant isotope supply is required throughout the study, additionally generating a need for coordination across multiple specialties. These factors can slow down recruitment and increase costs. As RLT becomes more widely adopted, commercial demand may outpace the ability to manufacture and deliver treatment. Scaling requires simultaneous expansion of isotope production, radiopharmaceutical manufacturing, logistics, trained personnel, treatment centers, and imaging capacity. Any one of these can become the limiting factor, disrupting the entire chain of supply.

Even with an approved product, many hospitals cannot deliver radioligand therapy because they lack the proper treatment infrastructure. This means market penetration depends on healthcare infrastructure as much as clinical demand. Successful commercialization requires specialists such as nuclear medicine physicians, radio pharmacists, medical physicists, radiation safety officers, trained nurses, and radiochemists. Many regions face workforce shortages, slowing adoption despite product availability. Referring oncologists may have limited familiarity with RLT compared with more conventional chemotherapy, targeted therapies, or immunotherapies. With misconceptions about radiation safety or a limited awareness of available treatment center, adoption may be slowed by a lack of proper market education, making education of both clinicians and patients an important commercial activity.

Artificial Intelligence and Informatics 

Figure 2. Potential applications of AI in RLT workflow. Sourced from Optimizing Cancer Treatment: Exploring the Role of AI in Radioimmunotherapy. 

Artificial intelligence (AI) is increasingly being integrated into RLT development and implementation. It is employed in automated lesion detection on PET scans, quantification of tumor burden, prediction of treatment response, optimization of treatment planning, and identification of patients most likely to benefit from therapy. Radioligand therapy requires precision dosimetry, but personalized absorbed-dose estimation remains challenging for many radiopharmaceutical therapies. Despite these challenges, artificial intelligence and quantitative imaging are expected to improve individualized dosimetry. Integration of AI has shown promise for contouring tumors, treatment planning, adaptive planning, outcome prediction, and toxicity prediction. Radiomics and machine learning are also being investigated to extract imaging features that may predict prognosis or therapeutic outcomes.

Expanding the capabilities of electronic laboratory notebooks (ELN), request and sample management, laboratory information management systems (LIMS), analysis, and reporting along with a proper scientific data environment to handle RLT research and development is integral to furthering this treatment. Integration of AI into these platforms can allow for better understanding of novel RLT isotopes and potential treatment techniques. The complexity of RLT ISDMTA (Ideate, Simulate, Design, Make, Test Analyze) cycle generates the need for R&D capabilities to simplify the process. A few ELN and LIMS platforms have radiochemistry capabilities suited to the development of RLT. For a report on the Radiochemistry aware tools send an email to info@20visioneers15.com.

Sources

Ninatti G, Lee ST, Scott AM. Radioligand Therapy in Cancer Management: A Global Perspective. Cancers (Basel). 2025 Oct 23;17(21):3412. doi: 10.3390/cancers17213412. PMID: 41228206; PMCID: PMC12607575.

Bowden GD, Scott PJH, Boros E. Radiochemistry: A Hot Field with Opportunities for Cool Chemistry. ACS Cent Sci. 2023 Nov 14;9(12):2183-2195. doi: 10.1021/acscentsci.3c01050. PMID: 38161375; PMCID: PMC10755734.

Currie G. Molecular theranostics: principles, challenges, and controversies. J Med Radiat Sci. 2025 Mar;72(1):156-164. doi: 10.1002/jmrs.836. Epub 2024 Nov 1. PMID: 39485717; PMCID: PMC11909690.

Jalloul W, Ghizdovat V, Pócza T, Saviuc A, Jalloul D, Grierosu IC, Stefanescu C. Targeted Alpha Therapy: Exploring the Clinical Insights into [225Ac]Ac-PSMA and Its Relevance Compared with [177Lu]Lu-PSMA in Advanced Prostate Cancer Management. Pharmaceuticals (Basel). 2025 Aug 18;18(8):1215. doi: 10.3390/ph18081215. Erratum in: Pharmaceuticals (Basel). 2026 Mar 16;19(3):485. doi: 10.3390/ph19030485. PMID: 40872606; PMCID: PMC12388893.

Turner JH. Human-Artificial Intelligence Symbiotic Reporting for Theranostic Cancer Care. Cancer Biother Radiopharm. 2025 Mar;40(2):89-95. doi: 10.1089/cbr.2024.0216. Epub 2024 Nov 5. PMID: 39501808.

Azadinejad H, Farhadi Rad M, Shariftabrizi A, Rahmim A, Abdollahi H. Optimizing Cancer Treatment: Exploring the Role of AI in Radioimmunotherapy. Diagnostics (Basel). 2025 Feb 6;15(3):397. doi: 10.3390/diagnostics15030397. PMID: 39941326; PMCID: PMC11816985.